

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: GOODWIN et al.

Serial No.: 09/079,785

Filed: May 15, 1998

For: CD30 LIGAND OLIGOMERS AND POLYPEPTIDES (as amended)



Docket No.: 2804-H

Group Art Unit: 1646

Examiner: L. Spector

#9/4B
ch
3-5-00

AMENDMENT A

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated September 13, 1999, please amend the above-identified application as follows:

In the Specification:

On page 1, line 7, please delete "CD30 LIGAND" (which is the current title) and replace with -- CD30 LIGAND OLIGOMERS AND POLYPEPTIDES --.

In the Claims:

Cancel claims 27-31, without prejudice.

Please amend claim 32 as follows:

1 32. (amended) A purified oligomer comprising CD30 ligand (CD30-L) polypeptides, wherein the CD30-L polypeptides are each selected from the group consisting of:

- a) the murine CD30-L of SEQ ID NO:6;
- b) the murine CD30-L of SEQ ID NO:19;
- c) the human CD30-L of SEQ ID NO:8;
- d) the human CD30-L of SEQ ID NO:23; and
- e) a fragment of the CD30-L of (a), (b), (c), or (d)[;], wherein said [oligomer] fragment binds CD30.

REMARKS

This amendment is submitted in response to the Office Action dated September 13, 1999. Reconsideration of the subject application is requested, in view of the foregoing amendments and the following discussion.

76